Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells
- PMID: 7500025
- PMCID: PMC2192257
- DOI: 10.1084/jem.182.6.1801
Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells
Abstract
Oncostatin M (OSM) is a 28-kD glycoprotein recently identified as a growth factor for human multiple myeloma cells. It belongs to a family of distantly related cytokines that includes interleukin 6, ciliary neurotrophic factor, leukemia-inhibitory factor, and interleukin 11. These cytokines initiate signaling by inducing either homodimerization of gp130 or heterodimerization of gp130 with leukemia-inhibitory factor receptor beta components. Such dimerization in turn activates receptor-associated tyrosine kinases. In the present study using U266B1 human multiple myeloma cells, we show that OSM induces tyrosine phosphorylation and activation of JAK2, but not JAK1 or Tyk2, kinases. The results also demonstrate that OSM induces direct interaction of JAK2 kinase with Grb2, an SH2/SH3 domain containing adaptor protein. The SH2 domain of Grb2 is directly associated with tyrosine-phosphorylated JAK2. Furthermore, the presence of Sos in the JAK2-Grb2 complex suggests a role for Ras in OSM-transduced signaling.
Similar articles
-
Shc mediates IL-6 signaling by interacting with gp130 and Jak2 kinase.J Immunol. 1997 May 1;158(9):4097-103. J Immunol. 1997. PMID: 9126968
-
Ciliary neurotrophic factor/leukemia inhibitory factor/interleukin 6/oncostatin M family of cytokines induces tyrosine phosphorylation of a common set of proteins overlapping those induced by other cytokines and growth factors.J Biol Chem. 1994 Apr 15;269(15):11648-55. J Biol Chem. 1994. PMID: 7512571
-
Contributions of leukemia inhibitory factor receptor and oncostatin M receptor to signal transduction in heterodimeric complexes with glycoprotein 130.J Immunol. 1999 Dec 15;163(12):6651-8. J Immunol. 1999. PMID: 10586060
-
GRB2: a pivotal protein in signal transduction.Semin Oncol. 2001 Oct;28(5 Suppl 16):142-7. doi: 10.1016/s0093-7754(01)90291-x. Semin Oncol. 2001. PMID: 11706405 Review.
-
Signaling via JAK tyrosine kinases: growth hormone receptor as a model system.Recent Prog Horm Res. 1998;53:61-82; discussion 82-3. Recent Prog Horm Res. 1998. PMID: 9769703 Review.
Cited by
-
Transcriptional and functional consequences of Oncostatin M signaling on young Dnmt3a-mutant hematopoietic stem cells.Exp Hematol. 2024 Feb;130:104131. doi: 10.1016/j.exphem.2023.11.005. Epub 2023 Nov 23. Exp Hematol. 2024. PMID: 38000729 Free PMC article.
-
The perspectives of interleukin-10 in the pathogenesis and therapeutics of multiple myeloma.Tzu Chi Med J. 2020 Dec 4;33(3):257-262. doi: 10.4103/tcmj.tcmj_141_20. eCollection 2021 Jul-Sep. Tzu Chi Med J. 2020. PMID: 34386363 Free PMC article. Review.
-
Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation.Mol Cell Biol. 2001 May;21(10):3547-57. doi: 10.1128/MCB.21.10.3547-3557.2001. Mol Cell Biol. 2001. PMID: 11313480 Free PMC article.
-
Preclinical studies of novel targeted therapies.Hematol Oncol Clin North Am. 2007 Dec;21(6):1071-91, viii-ix. doi: 10.1016/j.hoc.2007.08.013. Hematol Oncol Clin North Am. 2007. PMID: 17996589 Free PMC article. Review.
-
Multiple myeloma: increasing evidence for a multistep transformation process.Blood. 1998 Jan 1;91(1):3-21. Blood. 1998. PMID: 9414264 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous